

原著論文

2021 年（令和 3 年）

*は他教室への協力

1.Hachisuga K, Ohishi Y, Tomonobe H, Yahata H, Kato K, Oda Y.

Endometrial endometrioid carcinoma, G1, is more aggressive in the elderly than in the young.

Histopathology. 2021 Nov;79(5):708-719

2.Hongo T, Kuga R, Miyazaki M, Komune N, Nakano T, Yamamoto H, Koike K, Sato K, Kogo R, Nabeshima K, Oda Y, Nakagawa T.

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in temporal bone squamous cell carcinoma.

Laryngoscope. 2021 Dec;131(12):2674-2683

3.Hongo T, Yamamoto H, Jiromaru R, Nozaki Y, Yasumatsu R, Hashimoto K, Yoneda R, Sugii A, Taguchi K, Masuda M, Nakagawa T, Oda Y.

Clinicopathologic significance of EGFR mutation and HPV infection in sinonasal squamous cell carcinoma.

Am J Surg Pathol. 2021 Jan;45(1):108-118

4.Hongo T, Yamamoto H, Jiromaru R, Yasumatsu R, Kuga R, Nozaki Y, Hashimoto K, Matsuo M, Wakasaki T, Tamae A, Taguchi K, Toh S, Masuda M, Nakagawa T, Oda Y.

PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.

Mod Pathol. 2021 Nov;34(11):1966-1978

5.Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y.

The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.

J Cancer Res Clin Oncol. 2021 Jul;147(7):2003-2011

6.Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y.

PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma: the associations with tumor infiltrating lymphocytes, dMMR and HLA class I.

Oncol Rep. 2021 Jan;45(1):379-389

7.Ito Y, Kohashi K, Endo M, Yoshimoto M, Ishihara S, Toda Y, Susuki Y, Kawaguchi K, Furukawa H, Tateishi Y, Yamada Y, Kinoshita I, Mori T, Yamamoto H, Nakashima Y, Oda Y.

Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation.

Virchows Arch. 2021 Dec;479(6):1233-1244

8.Iwasaki T, Kohashi K, Toda Y, Ishihara S, Yamada Y, Oda Y.

Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.

J Cancer Res Clin Oncol. 2021 May;147(5):1451-1463

9.Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Nakano T, Hashimoto K, Nakagawa T, Oda Y.

p16 overexpression and Rb loss correlate with high-risk HPV infection in oropharyngeal squamous cell carcinoma.

Histopathology. 2021 Sep;79(3):358-369

10.Kinoshita I, Kohashi K, Yamamoto H, Yamada Y, Inoue T, Higaki K, Teramoto N, Oshiro Y, Nakashima Y, Oda Y.

Myxoepithelioid tumor with chordoid feature: a clinicopathological, immunohistochemical, and genetic study of 14 cases of SMARCB1/INI1-deficient soft-tissue neoplasm.

Histopathology. 2021 Oct;79(4):629-641

11.Kiyozawa D, Kohashi K, Takamatsu D, Yamamoto T, Eto M, Iwasaki T, Motoshita J, Shimokama T, Kinjo M, Oshiro Y, Yonemasu H, Oda Y.

Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity.

Hum Pathol. 2021 Jun;112:48-58

12.Kohashi K, Yamamoto H, Yamada Y, Kinoshita I, Oda Y.

Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid/rhabdoid tumor.

Hum Pathol. 2021 Jun;112:1-8

13.Mochidome N, Koga Y, Ohishi Y, Miyazaki T, Matsuda R, Yamada Y, Aishima S, Nakamura M, Oda Y.

Prognostic implications of the coexisting precursor lesion types in invasive gallbladder cancer.

Hum Pathol. 2021 Aug;114:44-53

14.Shibui Y, Kohashi K, Tamaki A, Kinoshita I, Yamada Y, Yamamoto H, Taguchi T, Oda Y.

The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.

J Cancer Res Clin Oncol. 2021 May;147(5):1499-1518

15.Tateishi Y, Yamada Y, Katsuki M, Nagata T, Yamamoto H, Kohashi K, Koga Y, Hashisako M,

Kiyozawa D, Mori T, Kuboyama Y, Kakinokizono A, Miyazaki Y, Yamaguchi A, Tsutsui H, Ninomiya T, Naiki H, Oda Y.

Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution.

Pathol Res Pract. 2021 Sep;227:153635

16.Toda Y, Kohashi K, Yamamoto H, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kiyozawa D,

Takamatsu D, Kinoshita I, Yamada Y, Maehara J, Kimura A, Tamiya S, Taguchi K, Matsunobu T, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.

Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.

Sci Rep. 2021 Jul;11(1):14821

17.Toda Y, Yamada Y, Kohashi K, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Kiyozawa D,

Mori T, Kuboyama Y, Tateishi Y, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.

Prognostic implication of desmoplastic stroma in synovial sarcoma: a histological review.

Pathol Res Pract. 2021 Dec;228:153668

18. Yamamoto H, Nozaki Y, Sugii A, Taguchi K, Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M, Oda Y.

Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.

Hum Pathol. 2021 Mar;109:37-44

19.*Fujisawa T, Horiike Y, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Kataoka K, Hashisako M, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.

Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias.

Respir Res. 2021 Nov;22(1):290

20.*Harada T, Iwasaki H, Muta T, Urata S, Sakamoto A, Kohno K, Takase K, Miyamura T, Sawabe T, Asaoku H, Oryoji K, Fujisaki T, Mori Y, Yoshimoto G, Ayano M, Mitoma H, Miyamoto T, Niiro H, Yamamoto H, Oshiro Y, Miyoshi H, Ohshima K, Takeshita M, Akashi K, Kato K.

Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.

Br J Haematol. 2021 Jul;194(1):101-110

21.*Haratake N, Hu Q, Okamoto T, Jogo T, Toyokawa G, Kinoshita F, Takenaka T, Tagawa T, Iseda N, Itoh S, Yamada Y, Oda Y, Shimokawa M, Kikutake C, Suyama M, Unoki M, Sasaki H, Mori M.

Identification of SLC38A7 as a prognostic marker and potential therapeutic target of lung squamous cell carcinoma.

Ann Surg. 2021 Sep;274(3):500-507

22.*Hashimoto H, Ito T, Ichiki T, Yamada Y, Oda Y, Furue M.

The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes.

J Clin Med. 2021 Feb;10(4):728

23.*Hashimoto H, Kaku-Ito Y, Oda Y, Ito T.

CDK4: A novel therapeutic target for extramammary paget's disease.

Front Oncol. 2021 Jul;11:710378

24.*Hatanaka Y, Kuwata T, Morii E, Kanai Y, Ichikawa H, Kubo T, Hatanaka KC, Sakai K, Nishio K, Fujii S, Okamoto W, Yoshino T, Ochiai A, Oda Y.

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.

Pathol Int. 2021 Nov;71(11):725-740

25.*Hu Q, Nonaka K, Wakiyama H, Miyashita Y, Fujimoto Y, Jogo T, Hokonohara K, Nakanishi R, Hisamatsu Y, Ando K, Kimura Y, Masuda T, Oki E, Mimori K, Oda Y, Mori M.

Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.

Cancer Med. 2021 May;10(9):3129-3138

26.*Ichimiya S, Onishi H, Nagao S, Koga S, Sakihama K, Nakayama K, Fujimura A, Oyama Y, Imaizumi A, Oda Y, Nakamura M.

GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.

Oncol Rep. 2021 Mar;45(3):997-1010

27.*Imamura Y, Toihata T, Haraguchi I, Ogata Y, Takamatsu M, Kuchiba A, Tanaka N, Gotoh O, Mori S, Nakashima Y, Oki E, Mori M, Oda Y, Taguchi K, Yamamoto M, Morita M, Yoshida N, Baba H, Mine S, Nunobe S, Sano T, Noda T, Watanabe M.

Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.

Int J Cancer. 2021 Mar;148(5):1260-1275

28.*Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Oda Y, Mori M.

Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.

Int J Clin Oncol. 2021 Oct;26(10):1890-1900

29.*Iseda N, Itoh S, Yoshizumi T, Yugawa K, Morinaga A, Tomiyama T, Toshima T, Kohashi K, Oda Y, Mori M.

ARID1A deficiency is associated with high programmed death ligand 1 expression in hepatocellular carcinoma.

Hepatol Commun. 2021 Apr;5(4):675-688

30.*Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M.

Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation.

Hepatol Commun. 2021 Mar;5(7):1278-1289

31.*Ito T, Tanegashima K, Tanaka Y, Hashimoto H, Murata M, Oda Y, Kaku-Ito Y.

Trop2 expression in extramammary paget's disease and normal skin.

Int J Mol Sci. 2021 Jul;22(14):7706

32.*Jogo T, Oki E, Nakanishi R, Ando K, Nakashima Y, Kimura Y, Saeki H, Oda Y, Maehara Y, Mori M.

Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen species accumulation.

Gastric Cancer. 2021 Sep;24(5):1089-1099

33.*Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M.

Comprehensive molecular profiling broadens treatment options for breast cancer patients.

Cancer Med. 2021 Jan;10(2):529-539

34.*Kawasaki J, Toshima T, Yoshizumi T, Itoh S, Mano Y, Wang H, Iseda N, Harada N, Oda Y, Mori M.

Prognostic impact of Vessels that Encapsulate Tumor Cluster (VETC) in patients who underwent liver transplantation for hepatocellular carcinoma.

Ann Surg Oncol. 2021 Dec;28(13):8186-8195

35.*Kinoshita F, Tagawa T, Akamine T, Takada K, Yamada Y, Oku Y, Kosai K, Ono Y, Tanaka K, Wakasu S, Oba T, Osoegawa A, Shimokawa M, Oda Y, Hoshino T, Mori M.

Interleukin-38 promotes tumor growth through regulation of CD8 + tumor-infiltrating lymphocytes in lung cancer tumor microenvironment.

Cancer Immunol Immunother. 2021 Jan;70(1):123-135

36.*Koga N, Hu Q, Sakai A, Takada K, Nakanishi R, Hisamatsu Y, Ando K, Kimura Y, Oki E, Oda Y, Mori M.

Clinical significance of signal regulatory protein alpha (SIRP α) expression in esophageal squamous cell carcinoma.

Cancer Sci. 2021 Aug;112(8):3018-3028

37.*Kohsaka S, Hirata M, Ikegami M, Ueno T, Kojima S, Sakai T, Ito K, Naka N, Ogura K, Kawai A, Iwata S, Okuma T, Yonemoto T, Kobayashi H, Suehara Y, Hiraga H, Kawamoto T, Motoi T, Oda Y, Matsubara D, Matsuda K, Nishida Y, Mano H.

Comprehensive molecular and clinicopathological profiling of desmoid tumours.

Eur J Cancer. 2021 Jan;145:109-120

38.*Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

Cell. 2021 Sep;184(18):4753-4771.e27

39.*Kusafuka K, Yamada H, Ishino K, Maeda M, Yamanegi K, Baba S, Ohuchi T, Inagaki H, Yamamoto H, Iwasaki T, Tsuchiya C, Sugimura H, Suzuki M.

Salivary duct carcinoma with rhabdoid features-no or aberrant expression of e-cadherin and genetic changes in CDH1: immunohistochemical and genetic analyses of 17 cases.

Am J Surg Pathol. 2021 Apr;45(4):439-449

40.*Liu R, Ota K, Iwama E, Yoneshima Y, Tanaka K, Inoue H, Tagawa T, Oda Y, Mori M, Nakanishi Y, Okamoto I.

Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.

Lung Cancer. 2021 Aug;158:156-161

41.*Momii K, Fujiwara T, Mae T, Tokunaga M, Iwasaki T, Shiimoto K, Kubota K, Onizuka T, Miura T, Hamada T, Nakamura T, Itokawa T, Iguchi T, Yamashita A, Kikuchi N, Nakaie K, Matsumoto Y, Nakashima Y.

Risk factors for excessive postoperative sliding of femoral trochanteric fracture in elderly patients: a retrospective multicenter study.

Injury. 2021 Nov;52(11):3369-3376

42.*Morisaki T, Kubo M, Umabayashi M, Yew PY, Yoshimura S, Park JH, Kiyotani K, Kai M, Yamada M, Oda Y, Nakamura Y, Morisaki T, Nakamura M.

Neoantigens elicit T cell responses in breast cancer.

Sci Rep. 2021 Jun;11(1):13590

43.*Morita N, Murase T, Ueda K, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Otsuki N, Nibu KI, Inagaki H.

Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: a proposal of an objective grading system.

Cancer Sci. 2021 Mar;112(3):1184-1195

44.*Murayama Y, Kamitani T, Sagiyama K, Yamasaki Y, Hida T, Matsuura Y, Yasumatsu R, Yamamoto H, Yabuuchi H, Ishigami K.

Evaluation of MR imaging findings differentiating parotid basal cell adenomas from other parotid tumors.

Eur J Radiol. 2021 Nov;144:109980

45.*Naito Y, Tsuneki M, Fukushima N, Koga Y, Higashi M, Notohara K, Aishima S, Ohike N, Tajiri T, Yamaguchi H, Fukumura Y, Kojima M, Hirabayashi K, Hamada Y, Norose T, Kai K, Omori Y, Sakeda A, Noguchi H, Uchino K, Itakura J, Okabe Y, Yamada Y, Akiba J, Kanavati F, Oda Y, Furukawa T, Yano H. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy.

Sci Rep. 2021 Apr;11(1):8454

46.*Sakai A, Nakashima Y, Miyashita Y, Ao T, Kimura Y, Shinto E, Oki E, Shimokawa M, Ueno H, Oda Y, Mori M.

Histological categorization of the desmoplastic reaction is a predictor of patient prognosis in oesophageal squamous cell carcinoma.

Histopathology. 2021 Aug;79(2):219-226

47.*Sasaki T, Izumaru K, Hata J, Sakata S, Oishi E, Nagata T, Tsuboi N, Oda Y, Kitazono T, Yokoo T, Ninomiya T.

Serum NT-proBNP levels and histopathological myocardial fibrosis in autopsied cases from a Japanese community: the Hisayama Study.

J Cardiol. 2021 Sep;78(3):237-243

48.*Sasaki T, Nakagawa K, Hata J, Hirakawa Y, Shibata M, Nakano T, Tsuboi N, Oda Y, Kitazono T, Yokoo T, Ninomiya T.

Pathologic diabetic nephropathy in autopsied diabetic cases with normoalbuminuria from a Japanese community-based study.

Kidney Int Rep. 2021 Sep;6(12):3035-3044

49.*Shimada E, Endo M, Matsumoto Y, Tsuchihashi K, Ito M, Kusaba H, Nabeshima A, Nawata T, Maekawa A, Matsunobu T, Setsu N, Fujiwara T, Iida K, Nakagawa M, Hirose T, Kanahori M, Oyama R, Isobe T, Ariyama H, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Akashi K, Baba E, Nakashima Y.

Does the use of peripheral immune - related markers indicate whether to administer pazopanib, trabectedin, or eribulin to advanced soft tissue sarcoma patients?

J. Clin. Med. 2021 Oct;10(21):4972

50.*Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, Ueda S, Ushijima M, Nagakawa S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Oda Y, Eto M.

Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression.

Cancer Sci. 2021 Jan;112(1):323-330

51.*Sonoda S, Yoshimaru K, Yamaza H, Yuniartha R, Matsuura T, Yamauchi-Tomoda E, Murata S, Nishida K, Oda Y, Ohga S, Tajiri T, Taguchi T, Yamaza T.

Biliary atresia-specific deciduous pulp stem cells feature biliary deficiency.

Stem Cell Res Ther. 2021 Nov;12(1):582

52.*Tahara M, Fujino Y, Yamasaki K, Oda K, Kido T, Sakamoto N, Kawanami T, Kataoka K, Egashira R, Hashisako M, Suzuki Y, Fujisawa T, Mukae H, Suda T, Yatera K.

Exposure to PM 2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case-control study.

Respir Res. 2021 Mar;22(1):80

53.*Tanaka Y, Murata M, Oda Y, Furue M, Ito T.

Nectin cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target?

Biomedicines. 2021 Mar;9(4):355

54.*Tominaga J, Iwasawa T, Murota M, Arakawa H, Johkoh T, Yamano Y, Zaizen Y, Ichikado K, Hashisako M, Kondoh Y, Kataoka K, Okamoto M, Fujimoto K, Fukuoka J; Study Group of Creation of Radiological Paper from Japan in Diffuse Lung Disease.

Computed tomography findings of current nonspecific interstitial pneumonia based on the 2013 updated classification of idiopathic interstitial pneumonias: what is a characteristic of previously diagnosed nonspecific interstitial pneumonia excluded from the updated classification.

Jpn J Radiol. 2021 Jan;39(1):47-55

55.*Uchi R, Jiromaru R, Yasumatsu R, Yamamoto H, Hongo T, Manako T, Sato K, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T.

Genomic sequencing of cancer-related genes in sinonasal squamous cell carcinoma and coexisting inverted papilloma.

Anticancer Res. 2021 Jan;41(1):71-79

56.*Yamada M, Kubo M, Yamamoto H, Yamashita N, Kai M, Zaguirre K, Kaneshiro K, Shimazaki A, Hayashi S, Kawaji H, Mori M, Oda Y, Nakamura M.

Effect of the 2013 ASCO-CAP HER2 testing guideline on the management of IHC/HER2 2+ invasive breast cancer.

Anticancer Res. 2021 Aug;41(8):4143-4149

57.*Yamashita K, Kohashi K, Yamada Y, Akatsuka S, Ikuta K, Nishida Y, Toyokuni S, Oda Y.

Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.

Genes Chromosomes Cancer. 2021 Jan;60(1):26-37

58.*Yoshimaru K, Matsuura T, Yanagi Y, Obata S, Takahashi Y, Kajihara K, Ohmori A, Irie K, Hino Y, Shibui Y, Tamaki A, Kohashi K, Oda Y, Taguchi T.

Reevaluation of concurrent AChE and HE staining for hirschsprung's disease.

Pediatr Int. 2021 Sep;63(9):1095-1102

59.*Yoshiya S, Itoh S, Yoshizumi T, Yugawa K, Kurihara T, Toshima T, Harada N, Hashisako M, Yonemasu H, Fukuzawa K, Oda Y, Mori M.

Impact of capicua on pancreatic cancer progression.

Ann Surg Oncol. 2021 Jun;28(6):3198-3207

60.*Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M.

Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.

Sci Rep. 2021 Mar;11(1):5845

61.*Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M.

CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma.

Hepatol Commun. 2021 Feb;5(2):334-348

62.*Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Toshima T, Harada N, Kohashi K, Oda Y, Mori M.

Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.

Mod Pathol. 2021 Apr;34(4):798-807

63.*Yugawa K, Itoh S, Yoshizumi T, Morinaga A, Iseda N, Toshima T, Harada N, Kohashi K, Oda Y, Mori M.

Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.

Int J Clin Oncol. 2021 Oct;26(10):1901-1910

64.*Yugawa K, Yoshizumi T, Mano Y, Itoh S, Harada N, Ikegami T, Kohashi K, Oda Y, Mori M.

Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p.

Eur J Surg Oncol. 2021 Feb;47(2):384-393

65.*Yuniartha R, Yamaza T, Sonoda S, Yoshimaru K, Matsuura T, Yamaza H, Oda Y, Ohga S, Taguchi T. Cholangiogenic potential of human deciduous pulp stem cell-converted hepatocyte-like cells.

Stem Cell Res Ther. 2021 Jan;12(1):57

66.*Zaguirre K, Kai M, Kubo M, Yamada M, Kurata K, Kawaji H, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Morisaki T, Mori H, Oda Y, Chen S, Moriyama T, Shimizu S, Nakamura M.

Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.

Cancer Med. 2021 Mar;10(5):1605-1613